Carbapenem Resistance Is Common in African Neonatal Sepsis Isolates
African newborns suspected of sepsis are facing a substantial burden of carbapenem-resistant gram-negative bacteria, according to a systematic review and meta-analysis that pooled data from 36 studies published between 2010 and 2023. The combined prevalence reached 30.34% across the continent, a level that signals how often first-line broad-spectrum rescue therapy may be undermined in the neonatal unit before clinicians even have a culture result in hand.
In practical terms, this is not a marginal laboratory finding. Carbapenems are often reserved for the sickest newborns when resistance to other agents is likely or already documented, so a one-in-three resistance burden among gram-negative isolates places immediate pressure on empiric treatment choices. The study focused on neonates suspected of sepsis, the exact population in which delayed or ineffective therapy can allow bacteremia to progress quickly from fever or instability to shock, multiorgan injury, and death. In that setting, resistance does not simply complicate prescribing; it narrows the window for survival.
The investigators searched PubMed, Science Direct, Scopus, and Google Scholar for English-language studies conducted in Africa and used PRISMA methods, quality appraisal with the Joanna Briggs Institute tool, and STATA version 17 for analysis. Their design included cross-sectional and cohort studies, with subgroup analysis, funnel plot assessment, Egger’s regression testing, and sensitivity analysis to interrogate heterogeneity and publication bias. The final synthesis therefore reflects a broad regional picture rather than a single-country signal.
Organisms Driving the Resistance Burden in Neonates
Two organisms stood out repeatedly: A. baumannii and Pseudomonas spp. The pooled prevalence of carbapenem resistance reached 45.9% for A. baumannii and 43.0% for Pseudomonas spp., figures that are especially troubling because both organisms are well adapted to hospital environments and can persist on surfaces, devices, and hands despite standard infection-control efforts. In neonatal intensive care units, where invasive lines, ventilation, and prolonged hospitalization are common, those traits translate into efficient transmission potential.
Resistance to specific carbapenems followed a similar pattern. The pooled estimate for imipenem resistance was 35.57%, although the confidence interval was very wide, stretching from 0.67% to 70.54%, a sign of marked variability across included studies. Meropenem resistance was also substantial at 34.35% overall. For meropenem specifically, Pseudomonas spp. showed a pooled resistance prevalence of 29.2%, while A. baumannii reached 36.7%. Those numbers matter because both drugs are often treated as interchangeable rescue options, yet this analysis shows that susceptibility cannot be assumed even within the same antimicrobial class.
E. coli and K. pneumoniae emerged as the two most common isolates. In neonatal sepsis, those pathogens are clinically familiar and biologically adaptable, capable of acquiring resistance determinants that survive antibiotic pressure and spread within units where infection prevention is stretched thin. When carbapenem resistance accumulates in these species, the clinical result is more than an inconvenient antibiogram. Empiric regimens lose reliability, escalation becomes slower and less certain, and clinicians are forced to weigh broader toxicities or less familiar agents while the clock keeps running.
The pooled estimates also varied widely across the continent, reinforcing that resistance is not distributed evenly. Local ecology, antibiotic access, stewardship practices, laboratory capacity, and hospital infection-control resources can all shape the level of resistance observed in a given setting. A neonate in one regional referral hospital may face a resistance profile very different from one in a neighboring health system, which means bedside decisions must be anchored in local microbiology rather than continental averages alone.
Stewardship, Surveillance, and Laboratory Capacity Now Carry Direct Weight
The most important clinical implication is straightforward: neonatal sepsis protocols in Africa need to account for a high background prevalence of carbapenem resistance, especially where gram-negative pathogens dominate and where A. baumannii or Pseudomonas are plausible causes. Empiric treatment strategies that assume carbapenem activity can fail silently until a child worsens, and in neonatal medicine the consequences of that delay can be immediate. Rapid culture turnaround, susceptibility testing, and escalation pathways become central tools, not optional refinements.
This synthesis also points to a larger systems problem. High resistance rates do not arise in isolation; they reflect antibiotic selection pressure, transmission in crowded care environments, and inconsistent antimicrobial oversight. Strengthened stewardship programs can reduce unnecessary carbapenem exposure, while surveillance systems can map local resistance patterns and identify outbreaks before they spread through a neonatal ward. Infection prevention measures, including hand hygiene, environmental decontamination, and device-care bundles, remain just as important when the organisms involved are capable of surviving repeated antimicrobial assaults.
A brief line from the data carries the bedside message plainly: resistance is already common enough to influence empiric care decisions now.
The study’s authors called for urgent antimicrobial stewardship, improved surveillance, and effective treatment pathways for neonates with sepsis. The continent-wide variability makes that call even more pressing, because pooled prevalence alone cannot protect an individual newborn. The next step is not simply to know that resistance is high, but to ensure that each neonatal unit has current susceptibility data, reliable microbiology services, and treatment protocols that reflect the organisms actually circulating within its own walls. Without those supports, carbapenems will remain a shrinking safety net for some of the most vulnerable patients in the hospital.